Caris Life Sciences News and Activities

Caris Life Sciences is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Caris Life Sciences is a company listed under the stock ticker CAI (US).

Acquisition, funding and merger involving Caris Life Sciences.

• Caris Life Sciences has filed its IPO. Its stock ticker will be CAI. (posted on May 27 2025).

View the org chart displaying its 45 main executives

Most searched biographies at Caris Life Sciences

• David Halbert, Chairman, Founder and Chief Executive Officer
• Lloyd Minor, Director
• Jonathan Knowles, Co-Vice Chairman of the Board

Create your alert
to follow the executive moves at Caris Life Sciences.

Caris Life Sciences has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Caris Life Sciences

• Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris’ Comprehensive Genomic Testing
• Caris Life Sciences to Present 32 Studies at ASCO 2026 Highlighting Advances in Multi-omic Biomarker Research and Real-World Evidence | Caris Life Sciences
• Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek
• Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood Based Testing Authorization
• New Study Showing Whole Exome Measurement of TMB Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels
• Caris Life Sciences Launches Caris MI Clarity
• Caris Life Sciences Reports First Quarter 2026 Financial Results | Caris Life Sciences
• Study Validates AI Insights for Temozolomide Benefit in Glioblastoma Patients
• Caris to Report Q1 2026 Financial Results
• Caris to present at BofA Securities & Goldman Sachs Conferences
• View more press releases Close

Social media about Caris Life Sciences

• Caris Life Sciences on Wikipedia, Google News & Yahoo Finance
• Caris Life Sciences on LinkedIn, X (Twitter) & YouTube